Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

GTX Inc (GTXI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 27,419
  • Shares Outstanding, K 24,052
  • Annual Sales, $ 0 K
  • Annual Income, $ -38,420 K
  • 60-Month Beta 2.60
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.06

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.62
  • Growth Rate Est. (year over year) +161,229.03%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.08 +5.56%
on 04/17/19
1.37 -16.79%
on 03/19/19
-0.18 (-13.64%)
since 03/18/19
3-Month
0.84 +35.71%
on 02/20/19
2.56 -55.47%
on 03/07/19
+0.18 (+18.75%)
since 01/18/19
52-Week
0.74 +54.05%
on 12/24/18
25.60 -95.55%
on 09/13/18
-15.49 (-93.14%)
since 04/18/18

Most Recent Stories

More News
Factors of Influence in 2019, Key Indicators and Opportunity within Adobe, CareTrust REIT, Ball, Equinix, Assembly Biosciences, and GTx -- New Research Emphasizes Economic Growth

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Adobe Systems Incorporated (NASDAQ:ADBE),...

BLL : 58.51 (+2.56%)
ADBE : 270.57 (+0.42%)
ASMB : 16.57 (+2.98%)
CTRE : 23.39 (+1.34%)
EQIX : 446.44 (-0.24%)
GTXI : 1.14 (-0.87%)
INVESTOR ALERT: Monteverde & Associates PC is Investigating the Recently Announced Acquisition

Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating:

NITE : 25.51 (+0.04%)
CTL : 12.14 (+0.25%)
BPI : 6.39 (unch)
COTY : 11.26 (+0.09%)
HF : 47.69 (+0.93%)
GTXI : 1.14 (-0.87%)
Lifshitz & Miller LLP Announces Investigation of Amarin Corporation plc, Clementia Pharmaceuticals Inc., CVS Health Corporation, Diplomat Pharmacy, Inc., GTx, Inc., Multi-Color Corporation, Osiris Therapeutics, Inc., and The Kraft Heinz Company

Amarin Corporation plc (AMRN)

CVS : 52.63 (+0.17%)
AMRN : 18.06 (+2.27%)
KHC : 32.96 (+0.21%)
CMTA : 26.35 (-0.11%)
OSIR : 18.99 (unch)
LABL : 49.86 (-0.06%)
DPLO : 5.41 (+3.84%)
GTXI : 1.14 (-0.87%)
Bragar Eagel & Squire, P.C. Reminds Investors that it is Investigating the Boards of Directors of Clementia, Multi-Color, and GTx on Behalf of Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. reminds investors that it is investigating potential claims on behalf of stockholders of Clementia Pharmaceuticals Inc., Multi-Color Corporation, and GTx, Inc. Additional information...

CMTA : 26.35 (-0.11%)
LABL : 49.86 (-0.06%)
GTXI : 1.14 (-0.87%)
GTX INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Merger of GTx, Inc. - GTXI

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed merger of GTx, Inc. (NasdaqCM: GTXI) with Oncternal Therapeutics,...

GTXI : 1.14 (-0.87%)
GTX, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Merger

Rigrodsky & Long, P.A.:

GTXI : 1.14 (-0.87%)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of GTx, Inc. to Oncternal Therapeutics, Inc. is Fair to Shareholders

The following statement is being issued by Levi & Korsinsky, LLP:

GTXI : 1.14 (-0.87%)
GTx and Oncternal Therapeutics Enter into Definitive Merger Agreement to Create Nasdaq-Listed Clinical-Stage Company Developing a Diverse Pipeline of Novel Cancer Therapies

-- Conference call to be held today at 8:30 a.m. Eastern Time/5:30 a.m. Pacific Time --

GTXI : 1.14 (-0.87%)
Analysis: Positioning to Benefit within Skyworks Solutions, Atmos Energy, Ellie Mae, ScanSource, REV Group, and GTx -- Research Highlights Growth, Revenue, and Consolidated Results

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Skyworks Solutions, Inc. (NASDAQ:SWKS),...

REVG : 12.19 (-1.06%)
ELLI : 98.99 (unch)
SCSC : 38.44 (-0.41%)
SWKS : 90.00 (-1.29%)
ATO : 99.18 (-0.26%)
GTXI : 1.14 (-0.87%)
GTx: 1Q Earnings Snapshot

MEMPHIS, Tenn. (AP) _ GTx Inc. (GTXI) on Tuesday reported a loss of $13.6 million in its first quarter.

GTXI : 1.14 (-0.87%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More Share

Trade GTXI with:

Business Summary

GTx, Inc. is a biopharmaceutical company dedicated to the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other serious medical conditions. GTx's lead candidate is enobosarm, a selective androgen receptor...

See More

Key Turning Points

2nd Resistance Point 1.20
1st Resistance Point 1.17
Last Price 1.14
1st Support Level 1.10
2nd Support Level 1.06

See More

52-Week High 25.60
Fibonacci 61.8% 16.10
Fibonacci 50% 13.17
Fibonacci 38.2% 10.24
Last Price 1.14
52-Week Low 0.74

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar